| scholarly article | Q13442814 |
| P2093 | author name string | Jae Ho Kim | |
| Benjamin Movsas | |||
| Mei Lu | |||
| Hans Stricker | |||
| Svend O Freytag | |||
| Kenneth Barton | |||
| P2860 | cites work | A Multiple Testing Procedure for Clinical Trials | Q28248823 |
| Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
| EQ-5D: a measure of health status from the EuroQol Group | Q34086093 | ||
| 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial | Q34341758 | ||
| Complications of androgen deprivation therapy: prevention and treatment. | Q35738817 | ||
| Prostate cancer gene therapy clinical trials | Q36779377 | ||
| Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation | Q36812634 | ||
| Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer | Q37107547 | ||
| The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome | Q39778167 | ||
| Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer | Q45866747 | ||
| A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy | Q45888206 | ||
| Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer | Q46656860 | ||
| Accurate Gleason grading of prostatic adenocarcinoma in prostate needle biopsies by general pathologists. | Q52953160 | ||
| Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. | Q54034626 | ||
| Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. | Q55041226 | ||
| Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin | Q59364974 | ||
| Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer | Q59650976 | ||
| If almost nothing goes wrong, is almost everything all right? Interpreting small numerators | Q71752543 | ||
| Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer | Q73250827 | ||
| Surrogate end points for prostate cancer: what is prostate-specific antigen telling us? | Q73400663 | ||
| Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients | Q74272784 | ||
| Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial | Q74487230 | ||
| Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial | Q78365368 | ||
| Industry, FDA warm to "adaptive" trials | Q79297761 | ||
| Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians | Q80261875 | ||
| Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02 | Q80274942 | ||
| Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer | Q80508459 | ||
| Quality of life and satisfaction with outcome among prostate-cancer survivors | Q80917895 | ||
| Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials | Q80977700 | ||
| Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis | Q81401677 | ||
| Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group | Q83841990 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | suicide | Q10737 |
| prostate cancer | Q181257 | ||
| Adenoviridae | Q193447 | ||
| gene therapy | Q213901 | ||
| adaptive radiation therapy | Q180507 | ||
| P304 | page(s) | 453-460 | |
| P577 | publication date | 2011-02-12 | |
| P1433 | published in | Contemporary Clinical Trials | Q5164971 |
| P1476 | title | Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial) | |
| P478 | volume | 32 |
| Q38645128 | Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. |
| Q36357754 | Efficient multicistronic co-expression of hNIS and hTPO in prostate cancer cells for nonthyroidal tumor radioiodine therapy. |
| Q36534930 | Frontiers in Suicide Gene Therapy of Cancer |
| Q38094813 | Individual treatment response in attention-deficit/hyperactivity disorder: broadening perspectives and improving assessments |
| Q36602123 | Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types |
| Q33556564 | Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines |
| Q59349753 | Selective Ablation of Tumorigenic Cells Following Human Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cell Transplantation in Spinal Cord Injury |
| Q37347017 | Suicide Gene Therapy for Cancer - Current Strategies |
| Q100428137 | The changing face of gastric cancer: epidemiologic trends and advances in novel therapies |
| Q38997243 | Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy |
Search more.